Difference between revisions of "PSLNR"
(Created page with "PSLNR may be a candidate diagnosis and therapeutic target for PCa.<ref name="ref1" /> ==Annotated Information== ===Name===...") |
(→Expression) |
||
| (One intermediate revision by the same user not shown) | |||
| Line 6: | Line 6: | ||
Approved name:prostate enriched lncRNA | Approved name:prostate enriched lncRNA | ||
| − | HGNC ID | + | HGNC ID:54405 |
Alias symbol:LA16c-83F12.6 | Alias symbol:LA16c-83F12.6 | ||
| Line 17: | Line 17: | ||
===Regulation=== | ===Regulation=== | ||
PSLNR also significantly inhibited PCa proliferation by inducing cell apoptosis in a p53-dependent manner.<ref name="ref1" /> | PSLNR also significantly inhibited PCa proliferation by inducing cell apoptosis in a p53-dependent manner.<ref name="ref1" /> | ||
| − | ===Expression=== | + | ===Expression=== |
| − | PSLNR was specifically expressed in the prostate.<ref name="ref1" /> | + | [[File:PSLNR.png|thumb|300px|PSLNR exhibited a highly prostate‐specific expression pattern, with little to no expression in other human tissue types by using the GTEx cohort.<ref name="ref1"/>]] |
| + | PSLNR was specifically expressed in the prostate.<ref name="ref1" /> | ||
| + | |||
===Diseases=== | ===Diseases=== | ||
Prostate cancer (PCa)<ref name="ref1" /> | Prostate cancer (PCa)<ref name="ref1" /> | ||
| Line 25: | Line 27: | ||
*Department of Urology, Shanghai Four People's Hospital Affiliated to Tongji University School of Medicine, Shanghai, PR China.<ref name="ref1" /> | *Department of Urology, Shanghai Four People's Hospital Affiliated to Tongji University School of Medicine, Shanghai, PR China.<ref name="ref1" /> | ||
| − | ==References== | + | ==References== |
| + | <references> | ||
<ref name="ref1">Wang D, Wan X, Zhang Y, Kong Z, Lu Y, Sun X, Huang Y, Ji C, Li D, Luo J, Gu W, Wang C, Li Y, Xu Y. A novel androgen-reduced prostate-specific lncRNA, PSLNR, inhibits prostate-cancer progression in part by regulating the p53-dependent pathway. Prostate. 2019 Sep;79(12):1362-1377. doi: 10.1002/pros.23840. Epub 2019 Jul 3.</ref>(1) | <ref name="ref1">Wang D, Wan X, Zhang Y, Kong Z, Lu Y, Sun X, Huang Y, Ji C, Li D, Luo J, Gu W, Wang C, Li Y, Xu Y. A novel androgen-reduced prostate-specific lncRNA, PSLNR, inhibits prostate-cancer progression in part by regulating the p53-dependent pathway. Prostate. 2019 Sep;79(12):1362-1377. doi: 10.1002/pros.23840. Epub 2019 Jul 3.</ref>(1) | ||
</references> | </references> | ||
Latest revision as of 03:43, 19 February 2021
PSLNR may be a candidate diagnosis and therapeutic target for PCa.[1]
Contents
Annotated Information
Name
Approved symbol:PSLNR
Approved name:prostate enriched lncRNA
HGNC ID:54405
Alias symbol:LA16c-83F12.6
RefSeq ID:NR_132385
Characteristics
Please input information here.[1]
Function
PSLNR inhibited PCa progression via the p53-dependent pathway.[1]
Regulation
PSLNR also significantly inhibited PCa proliferation by inducing cell apoptosis in a p53-dependent manner.[1]
Expression
PSLNR exhibited a highly prostate‐specific expression pattern, with little to no expression in other human tissue types by using the GTEx cohort.[1]
PSLNR was specifically expressed in the prostate.[1]
Diseases
Prostate cancer (PCa)[1]
Labs working on this lncRNA
- State Key Laboratory of Genetic Engineering, Shanghai Engineering Research Center of Industrial Microorganisms, School of Life Science, Fudan University, Shanghai, PR China.[1]
- Department of Urology, Shanghai Four People's Hospital Affiliated to Tongji University School of Medicine, Shanghai, PR China.[1]
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 Wang D, Wan X, Zhang Y, Kong Z, Lu Y, Sun X, Huang Y, Ji C, Li D, Luo J, Gu W, Wang C, Li Y, Xu Y. A novel androgen-reduced prostate-specific lncRNA, PSLNR, inhibits prostate-cancer progression in part by regulating the p53-dependent pathway. Prostate. 2019 Sep;79(12):1362-1377. doi: 10.1002/pros.23840. Epub 2019 Jul 3.
